Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial

Summary

Trial Summary
The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:

Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: